Janus Global Life Sciences JJAGLX

Morningstar Rating

Fund Research and Analysis

by Karin Anderson

Janus Global Life Sciences has appeal, but it's not for everyone.

Investors looking to increase their health-care exposure should keep in mind that they may already have a hefty allocation, especially as diversified fund managers were beefing up their stakes in these firms for their defensive qualities during last year's downturn. Read more

Kudos

New manager has four years of prior experience as comanager and analyst on this fund.

New focus on risk shows promise.

Relatively low costs. Read more

Risks

Can be volatile due to hefty top positions.

The fund is willing to pay up for growth.

Does not have a consistent record of success. Read more

Strategy

Manager Andrew Acker searches across the globe and market-cap spectrum for fast-growing health-care names that are undervalued based on current and future cash-flow analysis. He focuses on core growth names, emerging growth stories, and opportunistic plays. Read more

Management

Andrew Acker, who has worked as an analyst and comanager on the fund since 1999, was promoted to sole portfolio manager in May 2007 when former since-inception manager Tom Malley left Janus. Acker has also comanaged Janus Aspen Global Life Sciences JGLIX since October 2004. Read more

Inside Scoop

Ever since its 1999 inception, results have been a mixed bag. Current manager Andrew Acker aims to temper issue-specific risk with a revamped risk framework in order to smooth out returns. Read more

First Name

Last Name

Email Address

Zip Code

Create Password

Verify Password

(6-15 characters; case sensitive)

What is your occupation or job title?

Select...

Your registration indicates agreement to the terms of use.

Picking Positions in Health Care
Watch more